April 14, 2016
April 14, 2016 - PRESSADVANTAGE -
TheProductLawyers.com reports on the information released by the U.S. Food and Drug Administration in reference to Invokana and Invokamet, type-2 diabetes drugs. The FDA has received many adverse event reports on the topic. Allegedly the drugs can reduce the bone density of the users and there is an increased risk of injury from bone fractures.
The warning label had noted bone fracture risk but the FDA required changes to the warnings so they would indicate bone fracture seemed to appear more frequently among patients taking Invokana than when compared to those taking only the placebo pills. The FDA noted that fractures from low trauma, such as falling from heights no higher than standing height, were noted as early as 12 weeks after initiating treatment.
According to the new information, fractures can occur easily for patients taking an SGLT2 inhibitor drug. The FDA mentioned a significant decrease in the patient's bone mineral density when they use the drug. The FDA drew attention to a study of 714 elderly patients, where some took Invokana while some did not. Those taking the drug showed increased bone loss within their hips and spine.
The FDA has closely monitored and studied the topic for several years due to the connection to increased bone loss. A public warning regarding bone fractures that were reported to be observed in the 2013 clinical trials was released by the Endocrinologic and Metabolic Drugs Advisory Committee.
Attorneys at Banville understand the seriousness of the health conditions that have recently been connected to SGLT2 inhibitor class drugs. They are currently working to ensure that all patients who have taken or are taking Invokana or another SGLT2 inhibitor class drug and have suffered adverse health events have an opportunity to explore all their legal rights in full. They are also offering complimentary Invokana consultations to individuals interested in seeking justice. Affected parties may be entitled to financial compensation.
For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792
###
For more information about ZofranLegal.com, contact the company here:
ZofranLegal.com
Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046
Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major birth defects.
Michael Monheit
1368 Barrowdale Road, Rydal, PA 19046
1-877-620-8411
michael@monheit.com
Visit Website
